New drug combo may tame immunotherapy skin rash without hurting cancer fight
Symptom relief
Not yet recruiting
This phase 2 trial tests JAK inhibitors (upadacitinib or tofacitinib) in 35 adults with solid tumors who have severe skin rashes from immunotherapy that didn't improve with steroids. The goal is to see if these pills can quickly relieve the rash and itching while allowing patient…
Phase: PHASE2 • Sponsor: Shixiu Wu • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC